Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma

被引:157
|
作者
Lee, June H. [1 ]
Haselkorn, Tmirah [1 ]
Borish, Larry [2 ]
Rasouliyan, Lawrence [3 ]
Chipps, Bradley E. [4 ]
Wenzel, Sally E. [5 ]
机构
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Virginia Hlth Syst, Charlottesville, VA USA
[3] ICON Clin Res, San Francisco, CA USA
[4] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA
[5] Univ Pittsburgh, Pittsburgh, PA USA
关键词
airway remodeling; difficult-to-treat asthma; irreversible airway obstruction; persistent airflow limitation; severe asthma;
D O I
10.1378/chest.07-0713
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens study is among the largest to assess persistent airflow limitation and the first to evaluate a wide range of potential risk factors in high-risk patients with severe or difficult-to-treat asthma. A better understanding is needed regarding factors associated with persistent airway obstruction; this study was performed to determine demographic and clinical characteristics associated with persistent airflow limitation. Methods: Data from adult patients (>= 18 years old) with severe or difficult-to-treat asthma were evaluated. Patients with COPD, obesity with a restrictive respiratory pattern, or a >= 30 pack-year history of smoking were excluded. Patients with persistent airflow limitation (postbronchodilator FEV1/FVC ratio <= 70% at two annual consecutive visits) and normal postbronchodilator FEV1/ FVC ratio (75 to 85%) were compared. Multivariate analysis identified factors independently associated with persistent airflow limitation. Results: Of 1,017 patients, 612 patients (60%) showed evidence of persistent airflow limitation. Risk factors were as follows: older age (odds ratio [OR] per 10 years, 1.4; 95 % confidence interval [CI], 1.3 to 1.6); male gender (OR, 4.5; 95% CI, 2.3 to 8.5); black ethnicity (OR, 2.2; 95% CI, 1.3 to 3.8); current or past smoking (OR, 3.9; 95% CI, 1.8 to 8.6; and OR, 1.6; 95% CI, 1.2 to 2.3, respectively); aspirin sensitivity (OR, 1.5; 95% CI, 1.0 to 2.4); and longer asthma duration (OR per 10 years, 1.6; 95% CI, 1.4 to 1.8). Protective factors were Hispanic ethnicity, higher education, family history of atopic dermatitis, pet(s) in the home, and dust sensitivity. Conclusions: Persistent airflow limitation is prevalent in patients with severe or difficult-to-treat asthma and is associated with identifiable clinical and demographic characteristics.
引用
收藏
页码:1882 / 1889
页数:8
相关论文
共 50 条
  • [21] The role of radiological imaging in the management of severe and difficult-to-treat asthma
    Aigbirior, Joshua
    Almaghrabi, Amer
    Lafi, Monder
    Mansur, Adel H.
    [J]. BREATHE, 2024, 20 (02)
  • [22] Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma
    Schatz, Michael
    Hsu, Jin-Wen Y.
    Zeiger, Robert S.
    Chen, Wansu
    Dorenbaum, Alejandro
    Chipps, Bradley E.
    Haselkorn, Tmirah
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (06) : 1549 - 1556
  • [23] Biologics in severe difficult-to-treat asthma: find the right niche!
    Humbert, M.
    [J]. EUROPEAN RESPIRATORY REVIEW, 2009, 18 (112): : 51 - 53
  • [24] Economic burden of impairment in children with severe or difficult-to-treat asthma
    Szefler, Stanley J.
    Zeiger, Robert S.
    Haselkorn, Tmirah
    Mink, David R.
    Kamath, Tripthi V.
    Fish, James E.
    Chipps, Bradley E.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (02) : 110 - 119
  • [25] Comparison of asthma exacerbations in pediatric and adult patients with severe or difficult-to-treat asthma
    Zeiger, Robert S.
    Chipps, Bradley E.
    Haselkorn, Tmirah
    Rasouliyan, Lawrence
    Simons, F. Estelle R.
    Fish, James E.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (05) : 1106 - 1108
  • [26] PERSISTENT AIRFLOW LIMITATION IN SEVERE ASTHMA: REMODELING OR UNCONTROLLED INFLAMMATION
    Watson, N.
    Upham, J.
    [J]. RESPIROLOGY, 2019, 24 : 107 - 107
  • [27] Systematic assessment of difficult-to-treat asthma
    Robinson, DS
    Campbell, DA
    Durharm, SR
    Pfeffer, J
    Barnes, PJ
    Chung, KF
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (03) : 478 - 483
  • [28] Markers of Severity in Difficult-To-Treat Asthma
    Bush, Andrew
    [J]. PEDIATRIC PULMONOLOGY, 2017, 52 : S36 - S37
  • [29] Targeted interventions for difficult-to-treat asthma
    Chipps, Bradley E.
    Harder, Julia M.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2007, 11 (01) : 11 - 20
  • [30] Dupilumab utility in difficult-to-treat asthma
    Walsh, Garry M.
    [J]. IMMUNOTHERAPY, 2019, 11 (04) : 261 - 264